Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 1.00 |
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180056 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180187 | 0.93 | HRH1 (0.88) | HRH1CCR3KCNH2 | |
| SCHEMBL180281 | 0.92 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL179983 | 0.92 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180180 | 0.92 | HRH1 (0.85) | HRH1CCR3KCNH2 | |
| SCHEMBL180269 | 0.90 | HRH1 (0.82) | HRH1CCR3KCNH2 | |
| SCHEMBL180354 | 0.90 | HRH1 (0.81) | HRH1CCR3KCNH2 | |
| SCHEMBL180079 | 0.90 | HRH1 (0.82) | HRH1CCR3KCNH2 | |
| SCHEMBL180359 | 0.87 | HRH1 (0.86) | HRH1CCR3KCNH2 | |
| SCHEMBL4616917 | 0.87 | HRH1 (0.80) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | US | disclosed |
| US-8314127-B2 | Piperidine derivatives | ASTRAZENECA AB (SE) | 2012-11-20 | — | — | US | disclosed |
| EP-1912941-B1 | PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2402316-A1 | Piperidine derivatives | AstraZeneca AB (Publ) (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20080207688-A1 | Novel Piperidine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1912941-A1 | NOVEL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007011293-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207688-A1 | Novel Piperidine Derivatives | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | HRH1 1870/4885CCR3 1/4885KCNH2 4861/4885 |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.